Join the club for FREE to access the whole archive and other member benefits.

Gabrielle Masson

Staff writer for Fierce Biotech

Gabrielle Masson is a staff writer for Fierce Biotech. Prior to Fierce, she worked at Becker's Hospital Review for almost three years, where she reported on public health and the pandemic. Gabrielle graduated from the University of Wisconsin-Madison in 2019 after studying creative writing and criminal justice in both Wisconsin and Cape Town, South Africa. A current resident of Chicago, Gabrielle spends her free time scouting out the best restaurants, curating playlists and writing poetry.


Visit website: https://www.fiercebiotech.com/person/gabrielle-masson-0

 gabrielle-masson-b70815157

 GabrielleMasso9

See also

FierceBiotech

Web resource providing the latest biotech news, articles, and resources related to biotech company news

Details last updated 16-Aug-2022

Articles written by Gabrielle Masson

Bit.bio cuts 25% of staff as it shifts from therapy development to lab research

Bit.bio cuts 25% of staff as it shifts from therapy development to lab research

FierceBiotech - 19-Mar-2025

Company aims to grow its product line and biotech partnerships

Gene therapy restores hearing in children with rare deafness

Gene therapy restores hearing in children with rare deafness

FierceBiotech - 24-Feb-2025

Regeneron’s DB-OTO offers new hope for genetic hearing loss

Cell therapy breakthrough offers new hope for type 1 diabetes

Cell therapy breakthrough offers new hope for type 1 diabetes

FierceBiotech - 08-Jan-2025

Early trial results show promise for insulin production without immune suppression

AI-developed drug improves lung function in idiopathic pulmonary fibrosis

AI-developed drug improves lung function in idiopathic pulmonary fibrosis

FierceBiotech - 12-Nov-2024

Drug improved chronic cough symptoms, contributing to a better quality of life\

Bioage prepares for IPO, targets obesity with new drug trials

Bioage prepares for IPO, targets obesity with new drug trials

FierceBiotech - 04-Sep-2024

Biotech firm Bioage plans public debut as it advances promising obesity treatments

Genentech discontinues cell therapy collaboration with Adaptimmune

Genentech discontinues cell therapy collaboration with Adaptimmune

FierceBiotech - 12-Apr-2024

The company remains focused on its independent cancer drug development

Nanoscope's gene therapy offers hope for patients blinded by inherited retinal disease

Nanoscope's gene therapy offers hope for patients blinded by inherited retinal disease

FierceBiotech - 26-Mar-2024

Phase 2 trial results show significant vision improvement, plans for FDA approval

AgeX credit running out with substantial doubt it can continue

AgeX credit running out with substantial doubt it can continue

FierceBiotech - 15-Aug-2022

Let's hope their research is either successful for the company or its successors